Does hormone treatment predispose patients to breast cancer?
Plavix is an effective drug given for the preventing blood clots after a heart attack. The drug is also given to persons with certain disorders of the blood vessels. The drug has to be taken with food or in empty stomach. Plavix should have to be taken with a full glass of water. Once you are
Full Post: Prevent strokes and heart attacks with Plavix
Breast cancer, the leading cause of death among women in France, is the most commonly occurring cancer in women.
Sporadic breast cancer, which is non-hereditary, turns out to be the most widespread, representing 85 to 90% of all cases, but remains the least well-known. Researchers at CNRS and CEA, working with a team from H?al Saint-Louis, have just discovered the cause of 50% of sporadic breast cancers. The results should also explain epidemiological studies which suggest that hormone treatment predisposes patients to breast cancer. The work is published in ‘Cancer Research’.
More than four out of five breast cancers are not related to hereditary factors. These cancers, which are called sporadic, are due to causes which were until recently considered complex and poorly understood. On the other hand, hereditary forms of cancer, which represent only 10 to 15% of breast cancers, have for years been the subjects of studies, work which has resulted in the identification of ten genes whose mutation increases the risk of cancer in an individual. Among these genes, nine are involved in the DNA damage response system, which is the collection of cell mechanisms that optimize the repair of DNA. The tenth gene codes for a protein which inhibits the action of the AKT1 enzyme. And among these ten genes, two are responsible for 50% of hereditary breast cancers: BRCA1 and BRCA2. Researchers from the “Radiobiologie moléculaire et cellulaire” (CNRS / CEA) lab took these data on hereditary cancers as the starting point for their research into non-hereditary forms.
A link between hereditary and sporadic cancers It turns out that the AKT1 protein is over-expressed in 50% of sporadic breast cancers. Could this protein play a key role in predisposition to non hereditary breast cancer? The researchers, seeking an answer to this question, were able to show that activation of AKT1 leads to the sequestration of the BRCA1 protein in the cytoplasm. This makes it impossible for the protein to penetrate the nucleus, which prevents it from fulfilling its role in DNA repair. The cell then behaves as if it had no BRCA1 gene, without involving a mutation (unlike hereditary forms, where the BRCA1 gene undergoes an alteration). This phenomenon is observed in 50% of sporadic tumors. These results show a single, previously undetected, link between sporadic and hereditary cancers: the DNA damage response system.
The researchers have also suggested that hormone treatment may confer upon patients a predisposition to breast cancer. As AKT1 is activated by hormones, hormone treatment could indeed, in some cases, result in the chronic activation of the molecule. If this is the case, it could lead to a deregulation of the BRCA1 gene, and, as a result, to breast cancer. These first results still need to be confirmed, something that the team led by Bernard Lopez will do soon through further laboratory and clinical studies.
Institut de radiobiologie cellulaire et moléculaire, which is part of the Department of Life Sciences. The team is led by Fabien Calvo, director of Inserm unit 716 “Cibles pharmacologiques dans les cancers”. http://www.cnrs.fr/
A baby girl about to be born in Britain will be the first to have been screened for a breast cancer causing gene. The baby’s mother, is due to give birth soon to the first British baby to have been screened to be free of a gene which can cause breast cancer. The baby’s parents
Full Post: Baby girl due soon will be minus breast cancer causing gene
Prophylactic salpingo-oophorectomy-removal of the ovaries and fallopian tubes–reduces the relative risk of breast cancer by approximately 50 percent and the risk of ovarian and fallopian tube cancer by approximately 80 percent in women who carry a mutation in the BRCA1 or BRCA2 gene, researchers report in the January 13 online issue of the Journal of
Full Post: Research confirms value of risk-reducing salpingo-oophorectomy for women with BRCA mutations
Cancer Research UK scientists have identified a long sought after enzyme that plays a critical role in a DNA repair pathway linked with inheritable breast and ovarian cancer, reveals research published in Nature. Familial breast cancers, such as those caused by mutation of the BRCA2 tumour suppressor, are caused by defects in a pathway that
Full Post: Scientists find DNA repair ’scissors’ after 18 year hunt
Women who have a strong family history of breast cancer are over four times more likely to develop the disease than the general population, according to research published in the British Journal of Cancer. This is the first time the risk for women who do not have a faulty BRCA gene but have one first-degree
Full Post: Breast cancer four times more likely in women with strong family history
The first genetic map of obesity has been constructed using DNA microarray technology. This result was published in Nature Genetics on January 18th 2009 by a research group led by CNRS senior researcher Philippe Froguel and Inserm researcher David Meyre from the laboratory “Génomique et physiologie moléculaire des maladies métaboliques” (1), in association with their
Full Post: First genetic map of obesity